AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6110582 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oral contraceptives
Number of subjects: 500
Study 31904309 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mL distilled water with 10-minute rest in a supine position
Number of subjects: 0
Study 31904309 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mL distilled water with 30-minute rest in a supine position
Number of subjects: 0
Study 31904309 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31422929 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months DAPT
Number of subjects: 1496
Study 31422929 — intervention group
Group type: COMPARATOR
Intervention: 12 months DAPT
Number of subjects: 1496
Study 27755225 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural Restorative Environment (NRE) intervention
Number of subjects: 40
Study 27755225 — intervention group
Group type: COMPARATOR
Intervention: Active control intervention
Number of subjects: 40
Study 25733482 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplement (LNS) fortified with multiple micronutrients (MMNs)
Number of subjects: 0
Study 25733482 — intervention group
Group type: COMPARATOR
Intervention: MMN supplement
Number of subjects: 0
Study 24657484 — intervention group
Group type: EXPERIMENTAL
Intervention: TG4040 followed by PEG‐IFNα/RBV for 48 weeks with 6 injections of TG4040 (group C)
Number of subjects: 153
Study 24657484 — intervention group
Group type: COMPARATOR
Intervention: PEG‐IFNα/RBV for 48 weeks (group A)
Number of subjects: 153
Study 24657484 — intervention group
Group type: COMPARATOR
Intervention: PEG‐IFNα/RBV for 4 weeks followed by PEG‐IFNα/RBV for 44 weeks with 6 injections of TG4040 (group B)
Number of subjects: 153
Study 22571226 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg once daily for 3 days)
Number of subjects: 32
Study 22571226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 19224888 — intervention group
Group type: EXPERIMENTAL
Intervention: SIMV plus pressure support
Number of subjects: 20
Study 19224888 — intervention group
Group type: COMPARATOR
Intervention: SIMV alone
Number of subjects: 20
Study 17473196 — intervention group
Group type: EXPERIMENTAL
Intervention: High trkC mRNA expression (>1x human cerebellum) and low c‐myc mRNA expression (<=1x human cerebellum)
Number of subjects: 133
Study 17473196 — intervention group
Group type: EXPERIMENTAL
Intervention: High c‐myc mRNA expression and low trkC mRNA expression
Number of subjects: 133
Study 17473196 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate risk group (remaining 78 patients)
Number of subjects: 133
Study 17473196 — intervention group
Group type: EXPERIMENTAL
Intervention: High trkC mRNA expression in M(0) stage patients
Number of subjects: 133
Study 17473196 — intervention group
Group type: EXPERIMENTAL
Intervention: Low trkC mRNA expression levels in M(0) stage patients
Number of subjects: 133
Study 10730025 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone reminder to the patient
Number of subjects: 120
Study 10730025 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone notification to the prescribing physician
Number of subjects: 120
Study 10730025 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcard reminder to the patient
Number of subjects: 120
Study 10730025 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcard notification to the prescribing physician
Number of subjects: 120
Study 10730025 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 8959472 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesopitron 20, 25, 30, 40, 45, 50, and 60 mg two times a day
Number of subjects: 42
Study 8959472 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesopitron 60 mg two times a day
Number of subjects: 42
Study 8959472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 8959472 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesopitron (various doses)
Number of subjects: 42
Study 1304766 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IGIV) 500 mg/kg
Number of subjects: 37
Study 1304766 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic treatment
Number of subjects: 37
Study 3997971 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulated early (48 to 72 hours) with an immediate, post‐operative, pneumatic splinting device
Number of subjects: 80
Study 3997971 — intervention group
Group type: COMPARATOR
Intervention: Did not ambulate early (NA)
Number of subjects: 80
Study 30293831 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine infusion
Number of subjects: 90
Study 30293831 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 90
Study 30500140 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone gel, 7.5%
Number of subjects: 2160
Study 26539881 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy for Seasonal Affective Disorder (CBT-SAD)
Number of subjects: 177
Study 26539881 — intervention group
Group type: COMPARATOR
Intervention: Light Therapy
Number of subjects: 177
Study 25274897 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (500 mg)
Number of subjects: 25
Study 25274897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 23106639 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance
Number of subjects: 162
Study 23106639 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppression
Number of subjects: 162
Study 23106639 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 162
Study 18848786 — intervention group
Group type: EXPERIMENTAL
Intervention: Estramustine (E) 840 mg/day divided into three daily administrations on days 1-5 plus DOC 70 mg/m² on day 2
Number of subjects: 25
Study 18848786 — intervention group
Group type: EXPERIMENTAL
Intervention: Estramustine (E) plus DOC
Number of subjects: 25
Study 18786729 — intervention group
Group type: EXPERIMENTAL
Intervention: ISST (International Suicide Prevention Trial Scale for Suicidal Thinking)
Number of subjects: 0
Study 18786729 — intervention group
Group type: EXPERIMENTAL
Intervention: CDS (Calgary Depression Scale)
Number of subjects: 0
Study 18786729 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall characteristics of patients with Type 1 events
Number of subjects: 0
Study 15800138 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil treatment
Number of subjects: 147
Study 15800138 — intervention group
Group type: COMPARATOR
Intervention: Control (no anti-Alzheimer drugs)
Number of subjects: 147
Study 12847672 — intervention group
Group type: EXPERIMENTAL
Intervention: Early DMARD group
Number of subjects: 238
Study 12847672 — intervention group
Group type: COMPARATOR
Intervention: Pyramid group
Number of subjects: 238
Study 10235572 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled mesh
Number of subjects: 92
Study 10235572 — intervention group
Group type: COMPARATOR
Intervention: Unstapled mesh
Number of subjects: 92
Study 9036478 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation programme (physical training, psychological action, control guidelines of risk factors)
Number of subjects: 180
Study 9036478 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 180
Study 1886733 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous turning
Number of subjects: 17
Study 1886733 — intervention group
Group type: COMPARATOR
Intervention: Intermittent turning
Number of subjects: 17
Study 31982039 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 222
Study 31982039 — intervention group
Group type: COMPARATOR
Intervention: Best available therapy
Number of subjects: 222
Study 28025868 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic exercise
Number of subjects: 10
Study 28025868 — intervention group
Group type: COMPARATOR
Intervention: Cycling
Number of subjects: 10
Study 28025868 — intervention group
Group type: COMPARATOR
Intervention: Walking
Number of subjects: 10
Study 27537360 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue LED light treatment (emission maximum: 453 nm), 3 times per week for 4 weeks
Number of subjects: 21
Study 27537360 — intervention group
Group type: COMPARATOR
Intervention: Contralateral control lesion (untreated)
Number of subjects: 21
Study 25047311 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% feracrylum citrate solution
Number of subjects: 108
Study 25047311 — intervention group
Group type: COMPARATOR
Intervention: Adrenaline (1:100,000)
Number of subjects: 108
Study 23150980 — intervention group
Group type: EXPERIMENTAL
Intervention: Onsite heart failure service
Number of subjects: 28
Study 23150980 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 28
Study 20522353 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical and ultrasound assessment (Group B)
Number of subjects: 50
Study 20522353 — intervention group
Group type: COMPARATOR
Intervention: Clinical assessment alone (Group A)
Number of subjects: 50
Study 17942609 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide-DC vaccine (3 million versus 10 million) administered intravenously or subcutaneously
Number of subjects: 18
Study 17942609 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide-DC vaccine
Number of subjects: 18
Study 15696987 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue light therapy
Number of subjects: 0
Study 15696987 — intervention group
Group type: COMPARATOR
Intervention: Topical 1% clindamycin solution
Number of subjects: 0
Study 12858441 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 88
Study 12858441 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D3 and calcium supplementation alone
Number of subjects: 88
Study 10805701 — intervention group
Group type: EXPERIMENTAL
Intervention: Light flashes (vision)
Number of subjects: 12
Study 10805701 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger vibrations (touch)
Number of subjects: 12
Study 10805701 — intervention group
Group type: EXPERIMENTAL
Intervention: Vision (attending right vs. left)
Number of subjects: 12
Study 10805701 — intervention group
Group type: EXPERIMENTAL
Intervention: Touch (attending right vs. left)
Number of subjects: 12
Study 10805701 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile stimuli with eyes open
Number of subjects: 12
Study 10805701 — intervention group
Group type: COMPARATOR
Intervention: Tactile stimuli with eyes closed
Number of subjects: 12
Study 8913976 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg of PGE2 gel
Number of subjects: 119
Study 8913976 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 mg of PGE2 gel
Number of subjects: 119
Study 1859518 — intervention group
Group type: EXPERIMENTAL
Intervention: CM 40907 (1200 mg)
Number of subjects: 12
Study 1859518 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA, 1000 mg)
Number of subjects: 12
Study 1859518 — intervention group
Group type: EXPERIMENTAL
Intervention: CM 40907 (600 mg and 900 mg)
Number of subjects: 12
Study 1859518 — intervention group
Group type: EXPERIMENTAL
Intervention: CM 40907
Number of subjects: 12
Study 6355052 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir treatment (200 mg, 5 times daily) for first episode HSV
Number of subjects: 350
Study 6355052 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir treatment for recurrent HSV
Number of subjects: 350
Study 6355052 — intervention group
Group type: COMPARATOR
Intervention: Placebo for first episode HSV
Number of subjects: 350
Study 6355052 — intervention group
Group type: COMPARATOR
Intervention: Placebo for recurrent HSV
Number of subjects: 350
Study 30362105 — intervention group
Group type: EXPERIMENTAL
Intervention: MIL priming condition
Number of subjects: 68
Study 30362105 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 68
Study 31504594 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-enzyme complex
Number of subjects: 8
Study 31504594 — intervention group
Group type: COMPARATOR
Intervention: Cornstarch-based diets with 31.3% CM
Number of subjects: 8
Study 28669365 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychogeriatric beds
Number of subjects: 0
Study 28669365 — intervention group
Group type: COMPARATOR
Intervention: Somatic beds
Number of subjects: 0
Study 28669365 — intervention group
Group type: EXPERIMENTAL
Intervention: National surveillance
Number of subjects: 0
Study 28669365 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly admitted dementia residents
Number of subjects: 0
Study 27376047 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole‐trimethoprim (SMZ/TMP)
Number of subjects: 50
Study 27376047 — intervention group
Group type: COMPARATOR
Intervention: Sulfamethoxazole‐trimethoprim (SMZ/TMP) plus ciprofloxacin
Number of subjects: 50
Study 24332218 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 671800 (200 mg twice daily)
Number of subjects: 146
Study 24332218 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg once daily)
Number of subjects: 146
Study 24332218 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate nasal spray (200 μg once daily)
Number of subjects: 146
Study 24332218 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 671800 (all doses)
Number of subjects: 146
Study 22134140 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-help for SAD
Number of subjects: 245
Study 22134140 — intervention group
Group type: EXPERIMENTAL
Intervention: Unguided self-help for SAD
Number of subjects: 245
Study 20465014 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 480
Study 20465014 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480
Study 16919758 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 90
Study 16919758 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 90
Study 16919758 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham EA
Number of subjects: 90
Study 16919758 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal individuals)
Number of subjects: 90
Study 15711245 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate surgery
Number of subjects: 0
Study 15711245 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic urinary retention with large residual urine volumes (greater than 300 ml)
Number of subjects: 0
Study 15711245 — intervention group
Group type: EXPERIMENTAL
Intervention: Detrusor instability and decreased bladder compliance
Number of subjects: 0
Study 15711245 — intervention group
Group type: EXPERIMENTAL
Intervention: Ureterovesicular junction obstruction from bladder remodeling
Number of subjects: 0
Study 15711245 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodic acute urinary retention, urinary tract infections, secondary hypertension
Number of subjects: 0
Study 12193309 — intervention group
Group type: EXPERIMENTAL
Intervention: Single enema (400 mg of PTU in 90 mL of sterile water)
Number of subjects: 15
Study 12193309 — intervention group
Group type: COMPARATOR
Intervention: Two suppositories of polyethylene glycol base (200 mg of PTU in each)
Number of subjects: 15
Study 12193309 — intervention group
Group type: EXPERIMENTAL
Intervention: Both forms of PTU (enema and suppository)
Number of subjects: 15
Study 12193309 — intervention group
Group type: EXPERIMENTAL
Intervention: Both forms of PTU
Number of subjects: 15
Study 9793286 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser preparation
Number of subjects: 103
Study 9793286 — intervention group
Group type: COMPARATOR
Intervention: Conventional mechanical preparation
Number of subjects: 103
Study 9793286 — intervention group
Group type: COMPARATOR
Intervention: Mechanical preparation
Number of subjects: 103
Study 9097768 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% apraclonidine
Number of subjects: 202
Study 9097768 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% apraclonidine
Number of subjects: 202
Study 2523548 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 20
Study 2523548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1071693 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological therapy
Number of subjects: 81
Study 1071693 — intervention group
Group type: COMPARATOR
Intervention: Low-sodium diet
Number of subjects: 81
Study 31355898 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-acupoint massage (SEAM) in addition to routine nursing interventions
Number of subjects: 66
Study 31355898 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing interventions
Number of subjects: 66
Study 27431570 — intervention group
Group type: EXPERIMENTAL
Intervention: Kang'ai Xiaoshui ointment
Number of subjects: 72
Study 27431570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 26083953 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccine
Number of subjects: 1660
Study 26083953 — intervention group
Group type: COMPARATOR
Intervention: PNEUMOVAX 23 (active control)
Number of subjects: 1660
Study 23870239 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol
Number of subjects: 82
Study 23870239 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine pump spray
Number of subjects: 82
Study 20975521 — intervention group
Group type: EXPERIMENTAL
Intervention: Dominant hand training
Number of subjects: 200
Study 20975521 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondominant hand training
Number of subjects: 200
Study 20975521 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 200
Study 20975521 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall training effect
Number of subjects: 200
Study 19132414 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Prompt L-Pop
Number of subjects: 0
Study 19132414 — intervention group
Group type: EXPERIMENTAL
Intervention: Two experimental formulations
Number of subjects: 0
Study 16960176 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A and beta-carotene supplementation
Number of subjects: 225
Study 16960176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study 15055228 — intervention group
Group type: EXPERIMENTAL
Intervention: Native lard (NL) diet for 28 days
Number of subjects: 4
Study 15055228 — intervention group
Group type: COMPARATOR
Intervention: Randomized lard (RL) diet for 28 days
Number of subjects: 4
Study 15055228 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,3‐tetradeuteriopalmitoyl‐2‐dideuteriolinoleoyl‐rac‐glycerol
Number of subjects: 4
Study 15055228 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,3‐dideuteriolinoleoyl‐2‐tetradeuteriopalmitoyl‐rac‐glycerol and 1,3‐hexadeuteriopalmitoyl‐2‐tetradeuteriolinoleoyl‐rac‐glycerol
Number of subjects: 4
Study 15055228 — intervention group
Group type: EXPERIMENTAL
Intervention: 1‐acylphosphatidylcholine
Number of subjects: 4
Study 11255136 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium phosphate supplementation (4,000 mg x day(-1) for 2 days)
Number of subjects: 8
Study 11255136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 9875688 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape procyanidin extracts (Leucoselect-phytosome) 300 mg, taken as two capsules daily for 5 days.
Number of subjects: 20
Study 9875688 — intervention group
Group type: COMPARATOR
Intervention: Placebo, taken as two capsules daily for 5 days.
Number of subjects: 20
Study 8090841 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity electrical stimulation using console stimulators
Number of subjects: 110
Study 8090841 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity electrical stimulation using portable, battery-powered stimulators
Number of subjects: 110
Study 2603606 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary dissection (Group A)
Number of subjects: 100
Study 2603606 — intervention group
Group type: COMPARATOR
Intervention: Axillary sampling (Group B)
Number of subjects: 100
Study 2603606 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary dissection plus irradiation (Group A)
Number of subjects: 100
Study 2603606 — intervention group
Group type: COMPARATOR
Intervention: Other forms of treatment (Group B)
Number of subjects: 100
Study 2603606 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary irradiation (Group A)
Number of subjects: 100
Study 1096645 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 0
Study 1096645 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 0
Study 1096645 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine
Number of subjects: 0
Study 1096645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31128926 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted training
Number of subjects: 770
Study 31128926 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced upper limb therapy (EULT)
Number of subjects: 770
Study 31128926 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 770
Study 31128926 — intervention group
Group type: COMPARATOR
Intervention: Robot-assisted training vs Usual care
Number of subjects: 770
Study 31128926 — intervention group
Group type: COMPARATOR
Intervention: EULT vs Usual care
Number of subjects: 770
Study 31128926 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted training vs EULT
Number of subjects: 770
Study 31128926 — intervention group
Group type: EXPERIMENTAL
Intervention: EULT
Number of subjects: 770
Study 27283343 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's Health Activity Motor Program (CHAMP), 540 minutes, 9-week intervention
Number of subjects: 38
Study 27283343 — intervention group
Group type: COMPARATOR
Intervention: Control group (free-play, n=16)
Number of subjects: 38
Study 25471305 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate energy-restricted diet for 10 weeks
Number of subjects: 12
Study 25471305 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline gene expression analysis
Number of subjects: 12
Study 25471305 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-intervention gene expression analysis
Number of subjects: 12
Study 22832202 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM)
Number of subjects: 96